Cargando…
Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
We investigated the incidence of cardiotoxicity, its risk factors, and the clinical course of cardiac function in patients with malignant lymphoma (ML) who received a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Among all ML patients who received a CHOP regimen with o...
Autores principales: | Nakayama, Takafumi, Oshima, Yoshiko, Kusumoto, Shigeru, Yamamoto, Junki, Osaga, Satoshi, Fujinami, Haruna, Kikuchi, Takaki, Suzuki, Tomotaka, Totani, Haruhito, Kinoshita, Shiori, Narita, Tomoko, Ito, Asahi, Ri, Masaki, Komatsu, Hirokazu, Wakami, Kazuaki, Goto, Toshihiko, Sugiura, Tomonori, Seo, Yoshihiro, Ohte, Nobuyuki, Iida, Shinsuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176145/ https://www.ncbi.nlm.nih.gov/pubmed/35845008 http://dx.doi.org/10.1002/jha2.110 |
Ejemplares similares
-
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020) -
Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
por: Karmali, Reem, et al.
Publicado: (2022) -
Autologous peripheral blood stem cell transplantation for Philadelphia chromosome‐positive acute lymphoblastic leukemia is safe but poses challenges for long‐term maintenance of molecular remission: Results of the Auto‐Ph17 study
por: Nishiwaki, Satoshi, et al.
Publicado: (2023) -
Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020) -
Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)